Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Oncobax-AK With Immunotherapy in Advanced Solid Tumors
2024-516711-24-00Phase 2Completed
- Sponsor
- EverImmune
- Start
- Oct 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of Oncobax AK in non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) (2 cohorts), sponsored by EverImmune. Primary endpoints: Phase 1 safety and tolerability and Phase 2 objective response rate (ORR) per iRECIST. Started Oct 2024; status: completed.
02
Drugs
Oncobax AK
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2024-516711-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516711-24-00.